Oculis Holding AG (NASDAQ:OCS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $41.50.

A number of analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Lifesci Capital assumed coverage on Oculis in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective on the stock. Bank of America dropped their target price on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. JPMorgan Chase & Co. assumed coverage on Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target on the stock. Finally, Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Oculis Stock Up 4.7%

Shares of OCS stock opened at $23.07 on Friday. Oculis has a one year low of $14.00 and a one year high of $23.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The stock has a fifty day moving average price of $19.92 and a 200 day moving average price of $18.97. The stock has a market cap of $1.21 billion, a P/E ratio of -9.15 and a beta of 0.31.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. Analysts predict that Oculis will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares during the last quarter. Aventura Private Wealth LLC bought a new position in shares of Oculis in the fourth quarter valued at approximately $80,000. Geode Capital Management LLC boosted its holdings in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares in the last quarter. Compagnie Lombard Odier SCmA grew its position in Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Bosun Asset Management LLC acquired a new stake in Oculis during the 2nd quarter valued at $378,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.